News Releases

- Top-Line Data from Phase 2 EMPhASIS Trial in Relapsing-Remitting Multiple Sclerosis Expected in Third Quarter 2020 -

Phase 1 Clinical Studies to begin in First Half of 2020

IMU-856 has the potential to address one of the putative root causes of inflammatory bowel disease without impairing the immune system

- Milestone Achieved Nine Months Ahead of Initial Schedule; Top-Line Data Expected in Q3 2020 -

Preclinical Findings Confirm Favorable Profile of IMU-838 as Compared to Teriflunomide in the Potential Treatment of Relapsing-Remitting Multiple Sclerosis

- Unblinded Data Review Committee Recommended Continuation of the Lowest, 10 mg Dose as well as the Highest, 45 mg Dose -

- Study Being Conducted in Collaboration with Investigators at Arizona State University and the Mayo Clinic -

- Phase 2 Trial in Relapsing-Remitting Multiple Sclerosis Expected to be the First Efficacy Read-Out of IMU‑838; Top-line Data Anticipated in Q3 2020 -

- Results confirm IMU-935 as a potent inverse agonist of RORϒt with an IC₅₀ of 24 nM, leading to potent inhibition of Th17 differentiation while allowing normal thymocyte maturation -

- Developing Oral Therapies with Best-in-Class Potential -

Of the Votes Received to Date, More than 98% are Voting in Favor of the Business Combination

Transaction Expected to Create NASDAQ-listed Biopharmaceutical Company Focused on Advancing Immunic‘s Compelling Pipeline of Clinical-Stage and Late Preclinical Assets

Immunic AG gains exclusive, worldwide rights to promising drug development program with novel target for treatment of inflammatory bowel disease

First patient with ulcerative colitis entered the ‘CALDOSE-1’ trial with Immunic’s oral investigational drug IMU-838, a best-in-class DHODH inhibitor

FDA has granted IND approval for Immunic’s oral investigational drug IMU-838

Two phase 1 studies for IMU-838 in healthy volunteers have been completed

Omega and Fund+ broaden Immunic’s investor base and add an additional EUR 10 million (USD 12 million) in equity financing

Series A financing round extended to EUR 21.7 Million